NetworkNewsBreaks – VistaGen Therapeutics Inc. (
Post# of 83
(Total Views: 108)
Posted On: 12/01/2020 4:33:07 PM
NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine
VistaGen Therapeutics (NASDAQ: VTGN) has appointed a new vice president of translational medicine. A pioneer in the development of neuroactive steroids known as pherines, Louis Monti, MD., PhD., developed the original scientific platform that enabled the early research and development of VistaGen’s PH94B and PH10. The two intranasal neuroactive steroid drug candidates (pherines) have potential for the rapid-onset treatment of anxiety and depression disorders, respectively. VistaGen is a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Throughout his career, Monti has researched neuroactive pherines and their potential as a treatment for anxiety and depression. His new role at VistaGen allows him to continue to assist with the late-stage clinical development of PH94B and PH10 as well as employ his impressive R&D background in working with neuroactive steroids to discover expansion opportunities for the company. “We have had the pleasure of working closely with Dr. Monti in a consultative capacity since 2018 to complement our efforts to develop PH94B and PH10 to improve the lives of millions of people worldwide who suffer from anxiety and depression disorders every day,” stated VistaGen CEO Shawn K. Singh in the press release. “As we approach several potentially significant milestones for these differentiated neuropsychiatric drug candidates in 2021 and beyond, Dr. Monti’s unique knowledge, expertise, and insight about their potential, as well as potential opportunities for further expansion of our CNS pipeline, will be valuable. We are excited that he has now joined us as a full-time member of our R&D team.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VistaGen Therapeutics (NASDAQ: VTGN) has appointed a new vice president of translational medicine. A pioneer in the development of neuroactive steroids known as pherines, Louis Monti, MD., PhD., developed the original scientific platform that enabled the early research and development of VistaGen’s PH94B and PH10. The two intranasal neuroactive steroid drug candidates (pherines) have potential for the rapid-onset treatment of anxiety and depression disorders, respectively. VistaGen is a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Throughout his career, Monti has researched neuroactive pherines and their potential as a treatment for anxiety and depression. His new role at VistaGen allows him to continue to assist with the late-stage clinical development of PH94B and PH10 as well as employ his impressive R&D background in working with neuroactive steroids to discover expansion opportunities for the company. “We have had the pleasure of working closely with Dr. Monti in a consultative capacity since 2018 to complement our efforts to develop PH94B and PH10 to improve the lives of millions of people worldwide who suffer from anxiety and depression disorders every day,” stated VistaGen CEO Shawn K. Singh in the press release. “As we approach several potentially significant milestones for these differentiated neuropsychiatric drug candidates in 2021 and beyond, Dr. Monti’s unique knowledge, expertise, and insight about their potential, as well as potential opportunities for further expansion of our CNS pipeline, will be valuable. We are excited that he has now joined us as a full-time member of our R&D team.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)